Sanmeet Deo

So that landscape is different in terms of what you're investing in.

You're not investing in a drug that people are going to be taking every day of their life.

You're investing in a drug that will hopefully help somebody get unstuck from resistant forms of mental health conditions and then get to start moving on with their life.

Well, I would say that one thing investors may not know

is psychedelic therapy is an interventional approach, much different than traditional psychopharm interventions where you're, you know, it's not a daily intervention.

This is more similar to something like TMS to treat depression where it's like, you know, one to six or whatever amount of times.

So, you know, most investors wouldn't understand that unless they went and really dove in a little bit.

So that landscape is different in terms of what you're investing in.

You're not investing in a drug that people are going to be taking every day of their life.

You're investing in a drug that will hopefully help somebody get unstuck from resistant forms of mental health conditions and then get to start moving on with their life.

So in that sense, you need to know what you're looking at in terms of if you want to look at things that mimic how these might work in terms of investing in it.

Well, what it's not is taking LSD in your backyard and staring at the sky for six hours and playing Grateful Dead.

Not knocking that, many of us have been there, but it's not that, right?

So it's a little different.

So what it is, is you're combining certain medicines that are being studied, psychedelic medicines that are being studied with therapy.

And that looks like the therapy has stages.

So you're doing therapy prior to doing the medicine.

So you're preparing for this in many different ways.

And then you have sessions typically with a therapist in the room during the sessions on the medicine.

And then you're doing work after.